Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Alto Neuroscience, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ANRO
New York
2834
www.altoneuroscience.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Alto Neuroscience, Inc.
Alto Neuroscience (ANRO) Reports Wider Quarterly Loss, Is The Premium Valuation Still Justified?
- Nov 18th, 2026 6:12 pm
Is UnitedHealth Group (UNH) Stock Outpacing Its Medical Peers This Year?
- Nov 17th, 2026 6:40 am
Alto Neuroscience, Inc. (ANRO) Upgraded to Buy: Here's What You Should Know
- Nov 16th, 2026 9:00 am
Wall Street Analysts Predict a 29.38% Upside in Alto Neuroscience, Inc. (ANRO): Here's What You Should Know
- Nov 16th, 2026 6:55 am
Alto Neuroscience faces pivotal 2027 as Jefferies flags three clinical catalysts
- Nov 11th, 2026 1:44 pm
Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- Nov 10th, 2026 2:05 pm
Alto Neuroscience (ANRO) Stock Looks Fully Priced On Book Value
- Nov 10th, 2026 1:10 am
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
- Nov 4th, 2026 4:57 am
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
- Nov 3rd, 2026 6:03 am
Here's Why You Should Add ANRO Stock to Your Portfolio Now
- Oct 14th, 2026 6:59 am
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
- Oct 13th, 2026 6:40 am
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
- Aug 27th, 2026 2:05 pm
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?
- Aug 16th, 2026 2:07 pm
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?
- Aug 16th, 2026 2:08 am
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans
- Aug 15th, 2026 9:16 pm
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Aug 12th, 2026 2:03 pm
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
- Jul 13th, 2026 5:47 am
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?
- Jul 2nd, 2026 1:58 pm
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
- Jun 15th, 2026 6:03 am
Scroll